Spectrum Pharmaceuticals (SPPI) Osake Kurssi

Spectrum Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Spectrum Pharmaceuticals Inc in the market are companies such as Pfizer Inc, Johnson & Johnson, Novartis AG, Roche Holding AG, and Bristol-Myers Squibb Company.

Spectrum Pharmaceuticals Inc, a leading biopharmaceutical company, has a rich history and background. Founded in 1987, the company focuses on developing and commercializing innovative therapies for challenging diseases. With a primary focus on hematology and oncology, Spectrum specializes in developing medicines that target unmet medical needs. Over the years, they have successfully launched several important drugs, including FOLOTYN® and KHAPZORY®, which have played a crucial role in improving patient outcomes. Their commitment to research, development, and commercialization has positioned Spectrum Pharmaceuticals as a trusted name in the biopharmaceutical industry. With a strong track record and dedication to advancing patient care, Spectrum continues to make significant contributions in the healthcare sector.

Spectrum Pharmaceuticals Inc has achieved several significant milestones. The company received FDA approval for its flagship product, FUSILEV, in 2011, enhancing its position in the oncology market. Spectrum also launched ZEVALIN, a radioimmunotherapy agent for treating relapsed or refractory non-Hodgkin's lymphoma, in partnership with Bayer Healthcare. Furthermore, the company expanded its product portfolio through acquisitions, including the purchase of Talon Therapeutics and Allos Therapeutics. Spectrum's dedication to innovation and strategic partnerships has enabled it to solidify its presence in the pharmaceutical industry and deliver value to its stakeholders.

Spectrum Pharmaceuticals Inc primarily operates in the United States.

Spectrum Pharmaceuticals Inc represents values of excellence, innovation, and patient-centricity. With a strong corporate philosophy focused on developing targeted therapies for challenging diseases, Spectrum is dedicated to improving the lives of patients through cutting-edge research and development. The company's commitment to fostering a culture of integrity, collaboration, and respect sets them apart in the pharmaceutical industry. Spectrum Pharmaceuticals Inc strives to create value for patients, shareholders, and healthcare providers by delivering high-quality and differentiated therapeutic options. With a customer-driven approach, Spectrum aims to positively impact healthcare outcomes while staying at the forefront of medical advancements.

10 analyytikkoa arvioi tällä hetkellä Spectrum Pharmaceuticals-osaketta: 0 suosittaa ostoa, 7 pitoa ja 3 myyntiä.

Spectrum Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Spectrum Pharmaceuticals-osake (SPPI) on listattuna 5 pörssissä, muun muassa: NASDAQ (SPPI), SIX (Zürich) (NTR.SW), Frankfurt (NTR.F), München (NTR.MU), Düsseldorf (NTR.DU).

Spectrum Pharmaceuticals Inc is a US-based publicly traded company that specializes in the development and marketing of cancer medications. The company is headquartered in Irvine, California and has been active in the industry since 1996. The company's business model includes providing cancer medications in various stages of clinical development, from preclinical research to market launch. With this approach, Spectrum Pharmaceuticals aims to meet the demand for innovative and effective cancer therapies. Spectrum Pharmaceuticals' product range includes several medications in different stages of development. One of the key products, already approved and commercially available in the US, is Belinostat, a histone deacetylase inhibitor (HDAC inhibitor) used for the treatment of peripheral T-cell lymphoma (PTCL). PTCL is a rare, aggressive cancer for which there is currently no specific treatment. Another product currently in clinical development is ROLONTIS, a pegylated granulocyte colony-stimulating factor (pegfilgrastim). ROLONTIS is intended for the treatment of neutropenia, a complication in cancer patients commonly caused by chemotherapy. Spectrum Pharmaceuticals also has other projects in its pipeline, including several in preclinical development. The company's goal is to offer a comprehensive range of cancer medications for a variety of cancer types. Another important aspect of Spectrum Pharmaceuticals' business model is collaboration with other companies and research institutions. The company has formed strategic partnerships with several biotech and pharmaceutical companies to conduct joint research and development projects. Through these partnerships, Spectrum Pharmaceuticals can expand its portfolio and share its resources and expertise with other companies. The company also pursues a growth strategy through mergers and acquisitions. In 2020, Spectrum Pharmaceuticals completed the acquisition of Hikma Pharmaceuticals' generic portfolio for US customers. The acquisition included 22 approvals for generic medications as well as a development team. Overall, Spectrum Pharmaceuticals focuses on a broad range of therapeutics to meet the demand for cancer medications. By collaborating with other companies and acquiring companies and product portfolios, the company aims to further expand its market position. Overall, Spectrum Pharmaceuticals' business model is focused on the development and marketing of cancer medications to meet the demand for innovative and effective cancer therapies. The company relies on a broad range of therapeutics and works closely with other companies and research institutions to expand its portfolio.

Liikevaihtoa ei voida laskea Spectrum Pharmaceuticals:lle tällä hetkellä.

Voittoa ei voida laskea Spectrum Pharmaceuticals:lle tällä hetkellä.

P/E-suhdetta ei voida laskea Spectrum Pharmaceuticals:lle tällä hetkellä.

P/S-suhdetta ei voida laskea Spectrum Pharmaceuticals:lle tällä hetkellä.

Spectrum Pharmaceuticals:n Eulpool-laatuscore on 1/10.

Spectrum Pharmaceuticals:n ISIN on US84763A1088. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Spectrum Pharmaceuticals:n WKN on 164623. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Spectrum Pharmaceuticals:n ticker on SPPI. Tämä pörssinoteeraus käytetään Spectrum Pharmaceuticals-osakkeiden kauppaan pörssissä.